Apogee Therapeutics, Inc.
DelistedCIK 1974640fmd_11PDVX58GM64PD4W8PV93X3K49Manufacturing · Biological Products, (No Diagnostic Substances)Template: Standard
Coverage: Apr 01, 2022 to Jun 30, 2026, 16 periods
| Line item | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Research and development | 68 | 168 | 215 |
| Total operating expenses | 93 | 217 | 286 |
| Operating income | (93) | (217) | (286) |
| Interest and investment income | 9 | 35 | 30 |
| Other non-operating income (expense) | 9 | 35 | 30 |
| Income before taxes | (84) | (182) | (256) |
| Income tax expense | 0 | 0 | 0 |
| Net income from continuing operations | (84) | (182) | (256) |
| Net income | (84) | (182) | (256) |
| Net income to common shareholders | (84) | (182) | (256) |